JAM
NTLA icon

Jupiter Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Jupiter Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3M Buy
1,849,507
+68,444
+4% +$958K 0.16% 164
2026
Q1 		$22.8M Buy
1,781,063
+743,145
+72% +$9.47M 0.12% 199
2025
Q4 		$9.33M Sell
1,037,918
-323,931
-24% -$4.46M 0.07% 222
2025
Q3 		$23.5M Buy
+1,361,849
New +$16.8M 0.2% 143

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Jupiter Asset Management's NTLA Position: Q2 2026 in Review

Jupiter Asset Management increased its Intellia Therapeutics (NTLA) stake by 3.8% in Q2 2026, buying an estimated $958K and bringing the position to 1,849,507 shares worth $31.3M. The position accounts for 0.16% of the portfolio, ranked #164.

Jupiter Asset Management first reported a position in NTLA in Q3 2025 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Jupiter Asset Management held 1,849,507 shares of Intellia Therapeutics worth $31.3M as of Q2 2026.
  • Jupiter Asset Management bought 68,444 Intellia Therapeutics shares in Q2 2026, an estimated $958K.
  • Intellia Therapeutics made up 0.16% of Jupiter Asset Management's portfolio in Q2 2026, its #164 holding.
  • Jupiter Asset Management first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.